» Articles » PMID: 38396263

Global Prevalence of Erectile Dysfunction and Its Associated Risk Factors Among Men with Type 1 Diabetes: a Systematic Review and Meta-analysis

Overview
Journal Int J Impot Res
Date 2024 Feb 24
PMID 38396263
Authors
Affiliations
Soon will be listed here.
Abstract

Various observational studies have examined the prevalence and determinants of erectile dysfunction (ED) in men with type 1 diabetes across different geographical areas. Nevertheless, a comprehensive systematic review and meta-analysis to consolidate the worldwide prevalence and risk factors remains lacking. Hence, the primary study objective was to perform an extensive systematic review and meta-analysis that specifically examined ED prevalence and determinants in men with type 1 diabetes. A thorough exploration was conducted by examining electronic databases, such as PubMed, Embase, and Web of Science. The general ED prevalence and a 95% confidence interval (CI) in men with type 1 diabetes were summarized. The relevant risk factors were analyzed by deriving a comprehensive odds ratio (OR) from merging the ORs using fixed- or random-effects models. The sources of heterogeneity were investigated using subgroup analyses and meta-regression. This systematic review and meta-analysis included 19 articles involving 3788 men with type 1 diabetes. The meta-analysis revealed that men with type 1 diabetes had a combined ED prevalence of 42.5% (95% CI: 34.3%-50.8%). This prevalence showed significant heterogeneity (I = 96.2%, P < 0.01). Meta-regression revealed that age (P = 0.016) and type 1 diabetes duration (P = 0.004) were significant causes of heterogeneity. Furthermore, the ED risk in men with type 1 diabetes was significantly influenced by age, type 1 diabetes duration, body mass index, glycated hemoglobin (HbA1c), retinopathy, and smoking habits (all P < 0.05). In summary, this systematic review and meta-analysis revealed a significant prevalence of ED in men with type 1 diabetes, highlighting the importance of clinicians addressing concerns regarding ED in this specific group of individuals.

Citing Articles

Evaluating the Impact of Continuous Glucose Monitoring on Erectile Dysfunction in Type 1 Diabetes: A Focus on Reducing Glucose Variability and Inflammation.

Tecce N, Menafra D, Progano M, Tecce M, Pivonello R, Colao A Healthcare (Basel). 2024; 12(18).

PMID: 39337164 PMC: 11430976. DOI: 10.3390/healthcare12181823.

References
1.
Atkinson M, Eisenbarth G, Michels A . Type 1 diabetes. Lancet. 2013; 383(9911):69-82. PMC: 4380133. DOI: 10.1016/S0140-6736(13)60591-7. View

2.
Melendez-Ramirez L, Richards R, Cefalu W . Complications of type 1 diabetes. Endocrinol Metab Clin North Am. 2010; 39(3):625-40. DOI: 10.1016/j.ecl.2010.05.009. View

3.
Xu G, Liu B, Sun Y, Du Y, Snetselaar L, Hu F . Prevalence of diagnosed type 1 and type 2 diabetes among US adults in 2016 and 2017: population based study. BMJ. 2018; 362:k1497. PMC: 6122253. DOI: 10.1136/bmj.k1497. View

4.
Yafi F, Jenkins L, Albersen M, Corona G, Isidori A, Goldfarb S . Erectile dysfunction. Nat Rev Dis Primers. 2016; 2:16003. PMC: 5027992. DOI: 10.1038/nrdp.2016.3. View

5.
MacDonald S, Burnett A . Physiology of Erection and Pathophysiology of Erectile Dysfunction. Urol Clin North Am. 2021; 48(4):513-525. DOI: 10.1016/j.ucl.2021.06.009. View